<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">101235741</journal-id>
<journal-id journal-id-type="pubmed-jr-id">32200</journal-id>
<journal-id journal-id-type="nlm-ta">Am J Med Genet A</journal-id>
<journal-id journal-id-type="iso-abbrev">Am. J. Med. Genet. A</journal-id>
<journal-title-group>
<journal-title>American journal of medical genetics. Part A</journal-title>
</journal-title-group>
<issn pub-type="ppub">1552-4825</issn>
<issn pub-type="epub">1552-4833</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30194907</article-id>
<article-id pub-id-type="pmc">6209526</article-id>
<article-id pub-id-type="doi">10.1002/ajmg.a.40387</article-id>
<article-id pub-id-type="manuscript">NIHMS974861</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Understanding the Pediatric Psychiatric Phenotype of 22q11.2 Deletion Syndrome</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Fiksinski</surname>
<given-names>A.M.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Schneider</surname>
<given-names>M.</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Murphy</surname>
<given-names>C.M.</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Armando</surname>
<given-names>M.</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Vicari</surname>
<given-names>S.</given-names>
</name>
<xref ref-type="aff" rid="A7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Canyelles</surname>
<given-names>J.M.</given-names>
</name>
<xref ref-type="aff" rid="A8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gothelf</surname>
<given-names>D.</given-names>
</name>
<xref ref-type="aff" rid="A9">9</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Eliez</surname>
<given-names>S.</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Breetvelt</surname>
<given-names>E.J.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Arango</surname>
<given-names>C.</given-names>
</name>
<xref ref-type="aff" rid="A10">10</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Vorstman</surname>
<given-names>J.A.S.</given-names>
</name>
<xref ref-type="aff" rid="A11">11</xref>
<xref ref-type="aff" rid="A12">12</xref>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Department of Psychiatry, Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, Utrecht, The Netherlands</aff>
<aff id="A2"><label>2</label>Dalglish Family 22q Clinic for Adults with 22q11.2 Deletion Syndrome, Toronto General Hospital, University Health Network, and Clinical Genetics Research Program, Centre for Addiction and Mental Health, Toronto, Ontario, Canada</aff>
<aff id="A3"><label>3</label>Developmental Imaging and Psychopathology Lab, Department of Psychiatry, School of Medicine, University of Geneva, Geneva, Switzerland</aff>
<aff id="A4"><label>4</label>Center for Contextual Psychiatry, Department of Neurosciences, KU Leuven, Leuven, Belgium</aff>
<aff id="A5"><label>5</label>Sackler Institute for Translational Neurodevelopment and Department of Forensic and Neurodevelopmental Sciences, King’s College London, Institute of Psychiatry, Psychology &amp; Neuroscience, London, UK</aff>
<aff id="A6"><label>6</label>Behavioural and Developmental Psychiatry Clinical Academic Group, Behavioural Genetics Clinic, Adult Autism and ADHD Service, South London and Maudsley Foundation NHS Trust, London, UK</aff>
<aff id="A7"><label>7</label>Child and Adolescence Neuropsychiatry Unit, Department of Neuroscience, Children Hospital Bambino Gesù, Rome, Italy</aff>
<aff id="A8"><label>8</label>Hospital Universitario Fundacion Alcorcon, 28922 Alcorcon, Espana</aff>
<aff id="A9"><label>9</label>Child and Adolescent Psychiatry Unit, Edmond and Lily Safra Children’s Hospital, Sheba Medical Center, Sagol School of Neuroscience and Sackler School of Medicine Tel Aviv University, Tel Aviv, Israel</aff>
<aff id="A10"><label>10</label>Child and Adolescent Psychiatry Department, Hospital General Universitario Gregorio Marañón, IiSGM, School of Medicine, Universidad Complutense, CIBERSAM, Madrid, Spain</aff>
<aff id="A11"><label>11</label>Department of Psychiatry, The Hospital for Sick Children and University of Toronto, Toronto, Ontario, Canada</aff>
<aff id="A12"><label>12</label>Program in Genetics and Genome Biology, Research Institute, The Hospital for Sick Children, Toronto, Ontario, Canada</aff>
<author-notes>
<corresp id="CR1"><bold>Corresponding author:</bold> Ania M. Fiksinski, MSc., University Medical Center Utrecht, KA. B01107, Heidelberglaan 100, P.O. Box 85500, 3508 GA, Utrecht, The Netherlands, T +31 88 7553275, <email>a.m.fiksinski@umcutrecht.nl</email></corresp>
<fn fn-type="COI-statement" id="FN1">
<p id="P36">All authors declare that there are no conflicts of interest in relation to the subject of this study.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>16</day>
<month>6</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>08</day>
<month>9</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<month>10</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>10</month>
<year>2019</year>
</pub-date>
<volume>176</volume>
<issue>10</issue>
<fpage>2182</fpage>
<lpage>2191</lpage>
<!--elocation-id from pubmed: 10.1002/ajmg.a.40387-->
<abstract id="ABS1">
<sec id="S1">
<title>Aim.</title>
<p id="P1">The purpose of this article is to provide an overview of current insights into the neurodevelopmental and psychiatric manifestations of 22q11.2 deletion syndrome (22q11DS) in children and adolescents.</p>
</sec>
<sec id="S2">
<title>Recent findings.</title>
<p id="P2">The pediatric neuropsychiatric expression of 22q11DS is characterized by high variability, both inter-individual and intra-individual (different expressions over the lifespan). Besides varying levels of intellectual disability, the prevalence of autism spectrum disorders, attention deficit disorders, anxiety disorders, and psychotic disorders in young individuals with 22q11DS is significantly higher than in the general population, or in individuals with idiopathic intellectual disability. Possible explanations for this observed phenotypic variability will be discussed, including genetic pleiotropy, gene-environment interactions, the age-dependency of phenotypes, but also the impact of assessment and ascertainment bias as well as the limitations of our current diagnostic classification system.</p>
</sec>
<sec id="S3">
<title>Implications.</title>
<p id="P3">The implications inferred by these observations mentioned above bear direct relevance to both scientists and clinicians. Observations regarding the neuropsychiatric manifestations in individuals with 22q11DS exemplify the need for a <italic>dimensional approach</italic> to neuropsychiatric assessment, in addition to our current categorical diagnostic classification system. The potential usefulness of 22q11DS as a <italic>genetic model</italic> to study the early phases of schizophrenia as well as the phenomenon of neuropsychiatric pleiotropy observed in many CNV’s will be delineated. From a clinical perspective, the importance of <italic>regular neuropsychiatric evaluations</italic> with attention to <italic>symptoms</italic> not always captured in diagnostic categories and of <italic>maintaining equilibrium</italic> between individual difficulties and competencies and environmental demands will be discussed.</p>
</sec>
</abstract>
<kwd-group>
<kwd>22q11DS</kwd>
<kwd>psychiatry</kwd>
<kwd>pleiotropy</kwd>
<kwd>pediatric psychiatry</kwd>
<kwd>clinical implications</kwd>
<kwd>schizophrenia</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>